Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 4, 2009, Pages 396-402

  Filipski, K K ^a,b   Mathijssen, R H ^c   Mikkelsen, T S ^a,d   Schinkel, A H ^e   Sparreboom, A ^a,b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EXCRETION; GENE EXPRESSION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE DISORDER; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; URINALYSIS; URINARY EXCRETION;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; KIDNEY DISEASES; MALE; MICE; MICE, KNOCKOUT; ORGANIC CATION TRANSPORT PROTEINS; ORGANIC CATION TRANSPORTER 1; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 70349440952     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.139     Document Type: Article

References (27)

1. Go, R.S. & Adjei, A.A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol. 17, 409-422 (1999).
2. Planting, A.S., van der Burg, M.E., de Boer-Dennert, M., Stoter, G. & Verweij, J. Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. Br. J. Cancer 68, 789-792 (1993).
3. Arany, I. & Safirstein, R.L. Cisplatin nephrotoxicity. Semin. Nephrol. 23, 460-464 (2003).
4. Berns, J.S. & Ford, P.A. Renal toxicities of antineoplastic drugs and bone marrow transplantation. Semin. Nephrol. 17, 54-66 (1997).
5. Yao, X., Panichpisal, K., Kurtzman, N. & Nugent, K. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 334, 115-124 (2007).
6. Caterson, R., Etheredge, S., Snitch, P. & Duggin, G. Mechanisms of renal excretion of cisdichlorodiamine platinum. Res. Commun. Chem. Pathol. Pharmacol. 41, 255-264 (1983).
7. Ludwig, T., Riethmüller, C., Gekle, M., Schwerdt, G. & Oberleithner, H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int. 66, 196-202 (2004).
8. Ciarimboli, G. et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 167, 1477-1484 (2005).
9. Zhang, S. et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 66, 8847-8857 (2006).
10. Filipski, K.K., Loos, W.J., Verweij, J. & Sparreboom, A. Interaction of Cisplatin with the human organic cation transporter 2. Clin. Cancer Res. 14, 3875-3880 (2008).
11. Vanwert, A.L., Bailey, R.M. & Sweet, D.H. Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G. Am. J. Physiol. Renal Physiol. 293, F1332-F1341 (2007).
12. Burger, H. et al. Interaction of platinum compounds with the human organic cation transporter hOCT2 (SLC22A2). AACR Meeting Abstracts, 698 (2008).
13. Litterst, C.L., LeRoy, A.F. & Guarino, A.M. Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplatinum(II) to animals. Cancer Treat. Rep. 63, 1485-1492 (1979).
14. Jonker, J.W. et al. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol. Cell. Biol. 21, 5471-5477 (2001).
15. Jonker, J.W., Wagenaar, E., Van Eijl, S. & Schinkel, A.H. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol. Cell. Biol. 23, 7902-7908 (2003).
16. Koepsell, H., Lips, K. & Volk, C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 24, 1227-1251 (2007).
17. Sweet, D.H., Miller, D.S., Pritchard, J.B., Fujiwara, Y., Beier, D.R. & Nigam, S.K. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J. Biol. Chem. 277, 26934-26943 (2002).
18. de Jongh, F.E. et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J. Clin. Oncol. 19, 3733-3739 (2001).
19. Safirstein, R., Winston, J., Moel, D., Dikman, S. & Guttenplan, J. Cisplatin nephrotoxicity: insights into mechanism. Int. J. Androl. 10, 325-346 (1987).
20. Stewart, D.J., Dulberg, C.S., Mikhael, N.Z., Redmond, M.D., Montpetit, V.A. & Goel, R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother. Pharmacol. 40, 293-308 (1997).
21. Song, I.S. et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin. Pharmacol. Ther. 84, 559-562 (2008).
22. Vlaming, M.L. et al. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin. Cancer Res. 14, 8152-8160 (2008).
23. Pabla, N., Murphy, R.F., Liu, K. & Dong, Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am. J. Physiol. Renal Physiol. 296, F505-F511 (2009).
24. Fujita, T., Urban, T.J., Leabman, M.K., Fujita, K. & Giacomini, K.M. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J. Pharm. Sci. 95, 25-36 (2006).
25. Pabla, N. & Dong, Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 73, 994-1007 (2008).
26. Shu, Y., Bello, C.L., Mangravite, L.M., Feng, B. & Giacomini, K.M. Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells. J. Pharmacol. Exp. Ther. 299, 392-398 (2001).
27. Loos, W.J. et al. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J. Clin. Oncol. 24, 1499-1506 (2006).